Angiogenèse
Les inhibiteurs de l'angiogenèse sont des composés qui interfèrent avec la formation de nouveaux vaisseaux sanguins, un processus crucial dans la croissance et la métastase des cancers. En inhibant l'angiogenèse, ces composés peuvent restreindre l'apport sanguin aux tumeurs, ralentissant ou arrêtant leur croissance. Les inhibiteurs de l'angiogenèse sont essentiels dans la recherche sur le cancer et le développement thérapeutique, offrant des informations sur les mécanismes de progression tumorale et proposant des traitements potentiels pour le cancer et d'autres maladies liées à l'angiogenèse. Chez CymitQuimica, nous offrons une large gamme d'inhibiteurs de l'angiogenèse de haute qualité pour soutenir vos recherches en oncologie et biologie vasculaire.
Sous-catégories appartenant à la catégorie "Angiogenèse"
- BTK(147 produits)
- Bcr-Abl(103 produits)
- EGFR(572 produits)
- FAK(71 produits)
- FLT(91 produits)
- Récepteur du facteur de croissance des fibroblastes (FGFR)(169 produits)
- JAK(246 produits)
- PDGFR(126 produits)
- RAAS(87 produits)
- Src(80 produits)
- Syk(37 produits)
- Thrombine(47 produits)
- VDA(2 produits)
- VEGFR(262 produits)
Affichez 6 plus de sous-catégories
1522 produits trouvés pour "Angiogenèse"
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
EGFR-IN-144
<p>EGFR-IN-144 (Compound 4B) inhibits EGFR (IC50=0.639 µg/mL) and tubulin polymerization (IC50=7.339 µg/mL). It exhibits cytotoxicity in various cancer cells with a GI50 at the nanomolar level. EGFR-IN-144 reduces the expression of mTOR, TNF-α, and IL-6, causes G1/S phase cell cycle arrest, and induces apoptosis.</p>Formule :C20H17Cl2N3O3Couleur et forme :SolidMasse moléculaire :418.273MET/PDGFRA-IN-2
<p>MET/PDGFRA-IN-2 (compound 8h) serves as an inhibitor of MET and PDGFRA proteins, promoting apoptosis in cells and impeding the proliferation of MET-positive</p>Formule :C29H29N7ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :491.59MTX-241F
<p>MTX-241F, a selective small molecule inhibitor, targets members of the EGFR and PI3 kinase families.</p>Formule :C20H14ClFN6Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :392.82ALK-IN-13
CAS :<p>ALK-IN-13 is an ALK inhibitor.</p>Formule :C29H39ClN7O2PCouleur et forme :SolidMasse moléculaire :584.1Axltide
CAS :Axltide mimics mouse Insulin receptor substrate 1, amino acids 979-989 with sequence KKSRGDYMTMQIG.Formule :C63H107N19O20S2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :1514.77DC-Srci-6649
CAS :<p>DC-Srci-6649 is a potent and selective inhibitor of c-Src kinase, effectively blocking its phosphorylation and stabilizing it in an inactive conformation.</p>Formule :C20H22Cl2N2O2SCouleur et forme :SolidMasse moléculaire :425.37DSPE-PEG2000-GE11
<p>DSPE-PEG2000-GE11 is a PEG compound composed of DSPE and an EGFR-targeting peptide (GE11). GE11 is applicable for cancer cells that overexpress EGFR. DSPE-PEG2000-GE11 is utilized in drug delivery.</p>Couleur et forme :Odour SolidPROTAC FLT-3 degrader 1
CAS :<p>PROTAC FLT-3 degrader 1 is a PROTAC FLT-3 degrader of internal tandem duplication (ITD)(IC50 0.6 nM),with anti-proliferative activity.</p>Formule :C52H61N9O9S2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :1020.23BW710
<p>BW710 is an orally active inhibitor specifically targeting fibroblast growth factor receptor 2 (FGFR2). It effectively inhibits the proliferation of BaF3-FGFR2 cells with an IC50 value of 2.8 nM. BW710 completely suppresses FGFR2 enzymatic activity and demonstrates selectivity among 75 tyrosine kinases, including FGFR1, FGFR3, and FGFR4, at a 1 μM concentration. Additionally, BW710 impedes FGFR2 signaling and selectively inhibits the proliferation of cancer cells driven by FGFR2. It exhibits promising pharmacokinetic properties, with an oral bioavailability of 29% in mice.</p>Formule :C28H29FN6O2SCouleur et forme :SolidMasse moléculaire :532.63Duligotuzumab
CAS :<p>Duligotuzumab is a dual-targeting anti-EGFR/HER3 mAb that blocks signaling and induces ADCC for tumors with poor prognosis.</p>Degré de pureté :95% - 95%Couleur et forme :LiquidSJ988497
CAS :<p>SJ988497: PROTAC JAK2 degrader, inhibits CRLF2r cell growth, degrades GSPT1, combines Ruxolitinib, linker, Pomalidomide; researched for ALL.</p>Formule :C36H36N10O5Couleur et forme :SolidMasse moléculaire :688.74Anticancer agent 271
<p>Anticanceragent 271 (compound 5C) exhibits antiproliferative activity against lung cancer (A549), colon cancer (Caco-2) cell lines, and human lung fibroblasts (WI38), with an IC50 value of 9.18 μM for A549 cells. This compound can downregulate PI3K and mTOR gene expression and is applicable in cancer research.</p>Couleur et forme :Odour SolidPROTAC EGFR degrader 8
CAS :<p>PROTAC EGFR degrader 8 (T-184) is a PROTAC that selectively degrades the epidermal growth factor receptor (EGFR) with a DC50 of 15.56 nM in HCC827 cells.</p>Formule :C40H46ClN11O5Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :796.32Src Inhibitor 4
<p>Src Inhibitor4 (Compound 18) is a derivative of KX-01 and functions as a Src inhibitor. It effectively disrupts tumor cells, damages microtubules, and induces cell cycle arrest, apoptosis, and immunogenic cell death. After introducing phenol or aniline functional groups, Src Inhibitor4 serves as a payload conjugation site for antibody-drug conjugates, showcasing antitumor activity.</p>Formule :C33H34N4O3Couleur et forme :SolidMasse moléculaire :534.648Si5-N14
CAS :<p>Si5-N14 is a key component of siloxane-linked lipid nanoparticles (SiLNP) with properties that enhance vascular repair and exhibit antitumor activity. In transgenic GFP mouse models, Si5-N14 mediates CRISPR-Cas9 editing. In Lewis lung carcinoma (LLC) tumor mouse models, it leads to the knockdown of vascular endothelial growth factor receptor 2 (VEGFR2), producing antitumor effects. Additionally, in mice with virus-induced lung injury, Si5-N14 facilitates the delivery of fibroblast growth factor-2 (FGF-2) mRNA, promoting vascular repair, oxygenation, and improved lung function. Si5-N14 shows potential for research in tumors, pneumonia, and cardiovascular diseases.</p>Formule :C78H160N6O5Si2Couleur et forme :SolidMasse moléculaire :1318.31EGFR-IN-78
<p>EGFR-IN-78 (compound A5), a 2-aminopyrimidine derivative, serves as a reversible EGFR C797S-TK inhibitor and an apoptosis inducer.</p>Formule :C23H32BrN7O2SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :550.51EGFR/COX-2-IN-1
<p>EGFR/COX-2-IN-1 is an EGFR/COX-2 inhibitor that effectively targets EGFRWT, EGFRT790M, COX-1, and COX-2 with IC50 values of 0.12, 0.076, 20.1, and 1.52 μM, respectively. It inhibits MCF-7, HT-29, and A-549 cells with IC50 values of 1.20, 5.14, and 14.81 μM, respectively. The compound induces apoptosis by upregulating Bax protein and downregulating Bcl-2 protein levels. Additionally, EGFR/COX-2-IN-1 significantly increases the proportion of cells in the G2/M phase in MCF-7 cells, demonstrating a broad-spectrum antitumor effect.</p>Formule :C20H17FN6O2S2Couleur et forme :SolidMasse moléculaire :456.52JAK1/STAT3-IN-1
<p>JAK1/STAT3-IN-1 (compound 4f) functions as an anti-atopic dermatitis (AD) agent by inhibiting the JAK1/STAT3 signaling pathway. It has an IC50 value of 2.17 μM for inhibiting NO production. Additionally, JAK1/STAT3-IN-1 improves skin conditions in AD-like mice by reducing inflammatory infiltration, suppressing the expression of p-JAK1/JAK1 and p-STAT3/STAT3, and alleviating the hyperimmune response induced by MC903 (Calcipotriol).</p>Formule :C30H33FN4O3SCouleur et forme :SolidMasse moléculaire :548.67Multi-kinase-IN-5
<p>Multi-kinase-IN-5 (compound 15c) is a multi-kinase inhibitory agent that shows significant inhibition against a range of protein kinases including RET, KIT,</p>Formule :C19H15N5O2SCouleur et forme :SolidMasse moléculaire :377.42JAK 3 inhibitor IV
CAS :<p>JAK 3 inhibitor IV (ZM 39923 hydrochloride) is a JAK1/3 inhibitor with pIC50 of 4.4/7.1, almost no activity to JAK2 and modestly potent to EGFR; also found to</p>Formule :C16H19NODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :241.33
